Clinical and Economic Evaluation of CAR-T Therapy compared to ASCT for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in China

This capstone project evaluated the clinical and economic value of CD19-directed CAR-T therapy compared with autologous stem-cell transplantation (ASCT) in Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The primary objectives were to estimate the incremental cost-effectiveness ratio (ICER) of CAR-T relative to ASCT per quality-adjusted life year (QALY) gained under real-world conditions by quantifying and comparing the total direct medical costs, and to interpret these results in the context of China’s official willingness-to-pay thresholds. Using detailed patient-level data from a leading hematology center in China, this project generated rigorous, locally informed evidence to guide clinical decision-making, reimbursement policy, and equitable resource allocation for this transformative therapy.